Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vitrectomy | 15 | 2021 | 23 | 5.820 |
Why?
|
Macular Edema | 10 | 2016 | 24 | 4.300 |
Why?
|
Angiogenesis Inhibitors | 10 | 2022 | 76 | 3.660 |
Why?
|
Tomography, Optical Coherence | 23 | 2021 | 209 | 3.350 |
Why?
|
Diabetic Retinopathy | 11 | 2018 | 44 | 3.170 |
Why?
|
Retinal Detachment | 5 | 2022 | 18 | 2.590 |
Why?
|
Dexamethasone | 6 | 2017 | 201 | 2.390 |
Why?
|
Visual Acuity | 16 | 2021 | 117 | 2.290 |
Why?
|
Vitreous Body | 8 | 2022 | 30 | 2.240 |
Why?
|
Bevacizumab | 7 | 2016 | 57 | 2.170 |
Why?
|
Glucocorticoids | 7 | 2016 | 179 | 2.100 |
Why?
|
Intravitreal Injections | 12 | 2022 | 49 | 2.010 |
Why?
|
Retinal Diseases | 5 | 2019 | 31 | 1.940 |
Why?
|
Wet Macular Degeneration | 4 | 2016 | 26 | 1.910 |
Why?
|
Macula Lutea | 4 | 2017 | 21 | 1.610 |
Why?
|
Retinal Perforations | 3 | 2022 | 8 | 1.490 |
Why?
|
Laser Coagulation | 3 | 2016 | 14 | 1.490 |
Why?
|
Eye Injuries, Penetrating | 3 | 2021 | 5 | 1.460 |
Why?
|
Eye Foreign Bodies | 3 | 2021 | 8 | 1.460 |
Why?
|
Triamcinolone Acetonide | 4 | 2015 | 13 | 1.410 |
Why?
|
Sclerostomy | 4 | 2017 | 4 | 1.250 |
Why?
|
Endotamponade | 4 | 2016 | 6 | 1.200 |
Why?
|
Retinal Vein Occlusion | 4 | 2016 | 18 | 1.200 |
Why?
|
Choroidal Neovascularization | 3 | 2016 | 28 | 1.160 |
Why?
|
Retina | 8 | 2021 | 115 | 1.140 |
Why?
|
Sclera | 3 | 2017 | 10 | 1.130 |
Why?
|
Vitreous Detachment | 2 | 2017 | 2 | 1.110 |
Why?
|
Tissue Adhesions | 2 | 2017 | 19 | 1.100 |
Why?
|
Fluorescein Angiography | 9 | 2018 | 57 | 1.040 |
Why?
|
Aging | 3 | 2017 | 710 | 1.040 |
Why?
|
Fovea Centralis | 4 | 2018 | 17 | 1.010 |
Why?
|
Eye Infections, Bacterial | 2 | 2016 | 5 | 0.990 |
Why?
|
Lens Implantation, Intraocular | 3 | 2016 | 7 | 0.990 |
Why?
|
Silicone Oils | 2 | 2016 | 2 | 0.960 |
Why?
|
Ophthalmology | 2 | 2015 | 23 | 0.950 |
Why?
|
Sleep Apnea, Obstructive | 2 | 2016 | 54 | 0.910 |
Why?
|
Lens, Crystalline | 2 | 2016 | 15 | 0.900 |
Why?
|
Aged, 80 and over | 16 | 2017 | 5128 | 0.890 |
Why?
|
Humans | 52 | 2022 | 59360 | 0.850 |
Why?
|
Aged | 24 | 2018 | 13416 | 0.840 |
Why?
|
Macular Degeneration | 5 | 2016 | 178 | 0.780 |
Why?
|
Male | 29 | 2021 | 27739 | 0.780 |
Why?
|
Tomography, X-Ray Computed | 2 | 2021 | 1526 | 0.770 |
Why?
|
Cataract Extraction | 3 | 2016 | 34 | 0.760 |
Why?
|
Suture Techniques | 3 | 2017 | 91 | 0.740 |
Why?
|
Cataract | 3 | 2016 | 52 | 0.730 |
Why?
|
Ophthalmologic Surgical Procedures | 1 | 2021 | 9 | 0.720 |
Why?
|
Vascular Endothelial Growth Factor A | 6 | 2016 | 197 | 0.720 |
Why?
|
Postoperative Complications | 4 | 2016 | 1202 | 0.710 |
Why?
|
Retinal Pigment Epithelium | 3 | 2016 | 31 | 0.700 |
Why?
|
Middle Aged | 23 | 2018 | 16317 | 0.690 |
Why?
|
Pentosan Sulfuric Polyester | 1 | 2019 | 1 | 0.670 |
Why?
|
Female | 28 | 2018 | 30705 | 0.670 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2019 | 14 | 0.660 |
Why?
|
Sutures | 2 | 2016 | 35 | 0.650 |
Why?
|
Multimodal Imaging | 1 | 2019 | 66 | 0.630 |
Why?
|
Models, Biological | 4 | 2018 | 1143 | 0.630 |
Why?
|
Minimally Invasive Surgical Procedures | 2 | 2016 | 98 | 0.620 |
Why?
|
Vitreoretinal Surgery | 1 | 2018 | 3 | 0.610 |
Why?
|
Video Recording | 1 | 2018 | 126 | 0.580 |
Why?
|
Antibodies, Monoclonal, Humanized | 3 | 2015 | 219 | 0.580 |
Why?
|
Virus Activation | 1 | 2017 | 23 | 0.580 |
Why?
|
Keratitis, Herpetic | 1 | 2017 | 10 | 0.570 |
Why?
|
Herpes Simplex | 1 | 2017 | 48 | 0.560 |
Why?
|
Teaching | 1 | 2018 | 152 | 0.560 |
Why?
|
Diathermy | 1 | 2017 | 2 | 0.550 |
Why?
|
Retinal Hemorrhage | 1 | 2016 | 7 | 0.540 |
Why?
|
Panuveitis | 1 | 2016 | 1 | 0.540 |
Why?
|
Lens Capsule, Crystalline | 1 | 2016 | 3 | 0.530 |
Why?
|
Eye Infections, Fungal | 1 | 2016 | 2 | 0.520 |
Why?
|
Education, Medical | 1 | 2018 | 177 | 0.520 |
Why?
|
Histoplasmosis | 1 | 2016 | 23 | 0.510 |
Why?
|
Vitreous Hemorrhage | 1 | 2016 | 3 | 0.510 |
Why?
|
Point Mutation | 1 | 2016 | 160 | 0.510 |
Why?
|
Choroid | 1 | 2016 | 26 | 0.510 |
Why?
|
Endophthalmitis | 1 | 2016 | 11 | 0.510 |
Why?
|
Drug Implants | 4 | 2017 | 15 | 0.510 |
Why?
|
Anti-Inflammatory Agents | 1 | 2017 | 164 | 0.500 |
Why?
|
Calcinosis | 1 | 2016 | 79 | 0.500 |
Why?
|
Prospective Studies | 7 | 2018 | 3067 | 0.500 |
Why?
|
Tissue Plasminogen Activator | 1 | 2016 | 125 | 0.490 |
Why?
|
Fibrinolytic Agents | 1 | 2016 | 163 | 0.490 |
Why?
|
Histiocytosis, Sinus | 1 | 2015 | 2 | 0.490 |
Why?
|
Choroid Diseases | 1 | 2015 | 5 | 0.490 |
Why?
|
Glycoproteins | 1 | 2016 | 186 | 0.480 |
Why?
|
Retrospective Studies | 10 | 2016 | 6071 | 0.480 |
Why?
|
Choroid Neoplasms | 1 | 2015 | 21 | 0.480 |
Why?
|
Granuloma | 1 | 2015 | 41 | 0.470 |
Why?
|
Syphilis | 1 | 2015 | 25 | 0.470 |
Why?
|
Retinal Necrosis Syndrome, Acute | 1 | 2014 | 1 | 0.460 |
Why?
|
Eye Infections, Viral | 1 | 2014 | 3 | 0.460 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 140 | 0.460 |
Why?
|
Electrocoagulation | 1 | 2014 | 12 | 0.460 |
Why?
|
Staphylococcal Infections | 1 | 2016 | 122 | 0.460 |
Why?
|
Lens Subluxation | 2 | 2016 | 2 | 0.460 |
Why?
|
Surgical Wound Dehiscence | 1 | 2014 | 14 | 0.460 |
Why?
|
Geographic Atrophy | 1 | 2014 | 20 | 0.440 |
Why?
|
RNA-Binding Proteins | 1 | 2016 | 386 | 0.430 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2014 | 89 | 0.420 |
Why?
|
Uveitis, Intermediate | 1 | 2013 | 1 | 0.420 |
Why?
|
Catheterization | 1 | 2013 | 111 | 0.420 |
Why?
|
Herpesvirus 4, Human | 1 | 2014 | 178 | 0.410 |
Why?
|
Foreign-Body Migration | 1 | 2013 | 20 | 0.410 |
Why?
|
Drainage | 1 | 2013 | 149 | 0.410 |
Why?
|
Scotoma | 1 | 2012 | 6 | 0.400 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 406 | 0.400 |
Why?
|
Cognition Disorders | 1 | 2014 | 215 | 0.400 |
Why?
|
Ketorolac Tromethamine | 1 | 2012 | 5 | 0.400 |
Why?
|
Eye Pain | 1 | 2012 | 4 | 0.400 |
Why?
|
Neuropsychological Tests | 1 | 2014 | 371 | 0.390 |
Why?
|
Diabetes Mellitus | 1 | 2017 | 515 | 0.390 |
Why?
|
Scleral Buckling | 1 | 2011 | 1 | 0.380 |
Why?
|
Magnetic Resonance Imaging | 1 | 2021 | 2060 | 0.380 |
Why?
|
Cryosurgery | 1 | 2011 | 26 | 0.370 |
Why?
|
Melanoma | 1 | 2015 | 329 | 0.370 |
Why?
|
Young Adult | 6 | 2021 | 4267 | 0.360 |
Why?
|
Adult | 13 | 2018 | 15669 | 0.360 |
Why?
|
Multiple Myeloma | 1 | 2016 | 325 | 0.360 |
Why?
|
Follow-Up Studies | 5 | 2016 | 2337 | 0.360 |
Why?
|
Membrane Proteins | 1 | 2016 | 850 | 0.360 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 202 | 0.340 |
Why?
|
Choroiditis | 1 | 2009 | 1 | 0.330 |
Why?
|
Retinal Vessels | 3 | 2018 | 18 | 0.330 |
Why?
|
Phacoemulsification | 1 | 2009 | 7 | 0.320 |
Why?
|
Pain | 1 | 2012 | 396 | 0.320 |
Why?
|
Tachyphylaxis | 1 | 2008 | 3 | 0.310 |
Why?
|
Intraoperative Complications | 1 | 2009 | 85 | 0.300 |
Why?
|
Case-Control Studies | 3 | 2017 | 1051 | 0.280 |
Why?
|
Semaphorins | 2 | 2016 | 4 | 0.270 |
Why?
|
Swine | 2 | 2018 | 352 | 0.250 |
Why?
|
Microsurgery | 2 | 2016 | 51 | 0.230 |
Why?
|
Sulfur Hexafluoride | 2 | 2016 | 3 | 0.230 |
Why?
|
Antibodies, Monoclonal | 1 | 2008 | 839 | 0.220 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2018 | 654 | 0.220 |
Why?
|
Adolescent | 4 | 2017 | 5824 | 0.220 |
Why?
|
Fluorocarbons | 2 | 2016 | 34 | 0.220 |
Why?
|
Exudates and Transudates | 2 | 2016 | 11 | 0.210 |
Why?
|
Analysis of Variance | 2 | 2017 | 589 | 0.210 |
Why?
|
Treatment Outcome | 4 | 2016 | 5284 | 0.200 |
Why?
|
Indocyanine Green | 2 | 2015 | 10 | 0.200 |
Why?
|
Coloring Agents | 2 | 2015 | 53 | 0.200 |
Why?
|
Child | 3 | 2016 | 4174 | 0.190 |
Why?
|
Intraocular Pressure | 2 | 2013 | 59 | 0.180 |
Why?
|
Diagnosis, Computer-Assisted | 2 | 2018 | 42 | 0.180 |
Why?
|
Drug Therapy, Combination | 2 | 2015 | 452 | 0.180 |
Why?
|
Pain Measurement | 2 | 2012 | 327 | 0.180 |
Why?
|
Severity of Illness Index | 2 | 2016 | 1479 | 0.170 |
Why?
|
Disease Models, Animal | 2 | 2018 | 2050 | 0.170 |
Why?
|
Cystitis, Interstitial | 1 | 2019 | 5 | 0.170 |
Why?
|
Early Diagnosis | 3 | 2018 | 92 | 0.160 |
Why?
|
Computer Simulation | 1 | 2022 | 458 | 0.160 |
Why?
|
Area Under Curve | 2 | 2018 | 141 | 0.160 |
Why?
|
Angiography | 1 | 2018 | 146 | 0.150 |
Why?
|
Automation | 1 | 2018 | 51 | 0.150 |
Why?
|
Bruch Membrane | 2 | 2015 | 7 | 0.140 |
Why?
|
Germany | 1 | 2017 | 52 | 0.140 |
Why?
|
Intraoperative Period | 1 | 2017 | 33 | 0.140 |
Why?
|
Furin | 1 | 2016 | 10 | 0.140 |
Why?
|
Animals | 6 | 2018 | 19651 | 0.140 |
Why?
|
Rats, Long-Evans | 1 | 2016 | 21 | 0.140 |
Why?
|
Models, Cardiovascular | 1 | 2017 | 76 | 0.130 |
Why?
|
Pseudophakia | 1 | 2016 | 2 | 0.130 |
Why?
|
Educational Measurement | 1 | 2018 | 211 | 0.130 |
Why?
|
Ocular Hypertension | 1 | 2016 | 7 | 0.130 |
Why?
|
Metaplasia | 1 | 2016 | 18 | 0.130 |
Why?
|
Polytetrafluoroethylene | 1 | 2016 | 18 | 0.130 |
Why?
|
Age Distribution | 1 | 2017 | 249 | 0.130 |
Why?
|
Retinoscopy | 1 | 2016 | 3 | 0.130 |
Why?
|
Plasmapheresis | 1 | 2016 | 18 | 0.130 |
Why?
|
Mice, Inbred C57BL | 4 | 2016 | 3231 | 0.130 |
Why?
|
Tertiary Care Centers | 1 | 2016 | 100 | 0.130 |
Why?
|
Staphylococcus epidermidis | 1 | 2016 | 10 | 0.130 |
Why?
|
Cyclophosphamide | 1 | 2016 | 75 | 0.130 |
Why?
|
Bortezomib | 1 | 2016 | 56 | 0.130 |
Why?
|
Continuous Positive Airway Pressure | 1 | 2016 | 30 | 0.130 |
Why?
|
Watchful Waiting | 1 | 2016 | 24 | 0.130 |
Why?
|
Polysomnography | 1 | 2016 | 55 | 0.130 |
Why?
|
Vision Disorders | 1 | 2016 | 59 | 0.120 |
Why?
|
Prevalence | 1 | 2019 | 1252 | 0.120 |
Why?
|
Needles | 1 | 2016 | 65 | 0.120 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2017 | 168 | 0.120 |
Why?
|
Reproducibility of Results | 3 | 2018 | 1561 | 0.120 |
Why?
|
Cytoskeletal Proteins | 1 | 2016 | 196 | 0.120 |
Why?
|
Combined Modality Therapy | 1 | 2016 | 355 | 0.120 |
Why?
|
Penicillins | 1 | 2015 | 29 | 0.120 |
Why?
|
Drug Costs | 1 | 2015 | 54 | 0.120 |
Why?
|
Drug Combinations | 1 | 2015 | 147 | 0.120 |
Why?
|
Blood Transfusion | 1 | 2016 | 150 | 0.120 |
Why?
|
Rats | 2 | 2016 | 1910 | 0.120 |
Why?
|
Infusions, Intravenous | 1 | 2015 | 164 | 0.120 |
Why?
|
Eye Enucleation | 1 | 2014 | 9 | 0.120 |
Why?
|
Conjunctiva | 1 | 2014 | 3 | 0.120 |
Why?
|
Observer Variation | 1 | 2015 | 205 | 0.120 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 1 | 2014 | 17 | 0.120 |
Why?
|
Acyclovir | 1 | 2014 | 19 | 0.120 |
Why?
|
Epithelium, Corneal | 1 | 2014 | 4 | 0.110 |
Why?
|
Valine | 1 | 2014 | 31 | 0.110 |
Why?
|
Reference Values | 1 | 2014 | 326 | 0.110 |
Why?
|
Vitreoretinopathy, Proliferative | 1 | 2013 | 3 | 0.110 |
Why?
|
Antigens, Viral | 1 | 2014 | 130 | 0.110 |
Why?
|
Viscosity | 1 | 2013 | 50 | 0.110 |
Why?
|
Capsid Proteins | 1 | 2014 | 92 | 0.110 |
Why?
|
Risk Factors | 2 | 2014 | 4984 | 0.110 |
Why?
|
ErbB Receptors | 1 | 2014 | 114 | 0.110 |
Why?
|
Incidence | 1 | 2017 | 1237 | 0.110 |
Why?
|
DNA, Viral | 1 | 2014 | 223 | 0.110 |
Why?
|
Chronic Disease | 1 | 2016 | 716 | 0.110 |
Why?
|
Anterior Chamber | 1 | 2013 | 5 | 0.100 |
Why?
|
Databases, Factual | 1 | 2016 | 813 | 0.100 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2018 | 635 | 0.100 |
Why?
|
HLA-B7 Antigen | 1 | 2012 | 2 | 0.100 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2012 | 16 | 0.100 |
Why?
|
Electroretinography | 1 | 2012 | 26 | 0.100 |
Why?
|
Ophthalmic Solutions | 1 | 2012 | 7 | 0.100 |
Why?
|
Tetracaine | 1 | 2012 | 7 | 0.100 |
Why?
|
Propoxycaine | 1 | 2012 | 5 | 0.100 |
Why?
|
Immunoglobulin G | 1 | 2014 | 446 | 0.100 |
Why?
|
Antibodies, Viral | 1 | 2014 | 292 | 0.100 |
Why?
|
Visual Fields | 1 | 2012 | 43 | 0.100 |
Why?
|
Anesthesia | 1 | 2012 | 48 | 0.090 |
Why?
|
Refractive Errors | 1 | 2011 | 9 | 0.090 |
Why?
|
Anesthetics, Local | 1 | 2012 | 68 | 0.090 |
Why?
|
Homeostasis | 1 | 2014 | 346 | 0.090 |
Why?
|
Physiology | 1 | 2011 | 5 | 0.090 |
Why?
|
Antiviral Agents | 1 | 2014 | 313 | 0.090 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2016 | 605 | 0.090 |
Why?
|
Sensitivity and Specificity | 3 | 2018 | 1093 | 0.090 |
Why?
|
Acute Disease | 1 | 2012 | 660 | 0.090 |
Why?
|
History, 21st Century | 1 | 2011 | 162 | 0.090 |
Why?
|
History, 20th Century | 1 | 2011 | 223 | 0.080 |
Why?
|
Mice | 4 | 2016 | 10292 | 0.080 |
Why?
|
Fundus Oculi | 1 | 2009 | 21 | 0.080 |
Why?
|
Corneal Edema | 1 | 2009 | 1 | 0.080 |
Why?
|
Syndrome | 1 | 2009 | 170 | 0.080 |
Why?
|
Cicatrix | 1 | 2009 | 59 | 0.080 |
Why?
|
Anti-Bacterial Agents | 1 | 2015 | 735 | 0.080 |
Why?
|
Retreatment | 1 | 2008 | 46 | 0.080 |
Why?
|
Injections | 1 | 2008 | 75 | 0.080 |
Why?
|
Software | 1 | 2011 | 367 | 0.070 |
Why?
|
Hemoglobins | 1 | 2008 | 133 | 0.070 |
Why?
|
Surveys and Questionnaires | 1 | 2014 | 2513 | 0.070 |
Why?
|
Time Factors | 1 | 2012 | 3617 | 0.060 |
Why?
|
Cell Line | 2 | 2016 | 1984 | 0.040 |
Why?
|
Calibration | 1 | 2018 | 67 | 0.040 |
Why?
|
Fluorescein-5-isothiocyanate | 1 | 2016 | 20 | 0.030 |
Why?
|
Pattern Recognition, Automated | 1 | 2017 | 51 | 0.030 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2016 | 33 | 0.030 |
Why?
|
Human Umbilical Vein Endothelial Cells | 1 | 2016 | 38 | 0.030 |
Why?
|
Dextrans | 1 | 2016 | 45 | 0.030 |
Why?
|
Endothelial Cells | 1 | 2016 | 173 | 0.030 |
Why?
|
Machine Learning | 1 | 2017 | 153 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 2016 | 490 | 0.030 |
Why?
|
Pilot Projects | 1 | 2018 | 914 | 0.030 |
Why?
|
Tears | 1 | 2014 | 4 | 0.030 |
Why?
|
Wound Healing | 1 | 2014 | 174 | 0.030 |
Why?
|
Ligands | 1 | 2014 | 411 | 0.030 |
Why?
|
Epithelial Cells | 1 | 2014 | 391 | 0.020 |
Why?
|
Apoptosis | 1 | 2016 | 1032 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2018 | 2373 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2014 | 2093 | 0.020 |
Why?
|
Rats, Inbred BN | 1 | 2008 | 25 | 0.020 |
Why?
|
alpha-Globins | 1 | 2008 | 5 | 0.020 |
Why?
|
beta-Globins | 1 | 2008 | 9 | 0.020 |
Why?
|
Erythroblasts | 1 | 2008 | 15 | 0.020 |
Why?
|
Peptide Mapping | 1 | 2008 | 28 | 0.020 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2008 | 39 | 0.020 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2008 | 81 | 0.020 |
Why?
|
Cytosol | 1 | 2008 | 171 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 446 | 0.020 |
Why?
|
Blotting, Western | 1 | 2008 | 584 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 527 | 0.020 |
Why?
|
Proteomics | 1 | 2008 | 263 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2008 | 847 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2008 | 1465 | 0.010 |
Why?
|